Related Experiment Video
Updated: May 21, 2026
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Current approaches and future directions in the treatment of HER2-positive breast cancer
Sara A Hurvitz1, Yufang Hu, Neil O'Brien
1University of California at Los Angeles, Los Angeles, CA 90095, USA. shurvitz@mednet.ucla.edu
Abstract:
Human epidermal growth factor receptor 2 (HER2), a member of the ErbB family of transmembrane receptor tyrosine kinases, is amplified in 20-30% of invasive breast cancers. HER2 amplification is associated with metastasis and reduced survival. Two HER2-directed therapies have been approved by the United States Food and Drug Administration for the treatment of HER2-overexpressing breast cancer: trastuzumab, a humanized monoclonal antibody against the extracellular portion of HER2; and lapatinib, a dual HER2- and epidermal growth factor receptor-specific tyrosine kinase inhibitor. Despite the improvement in overall survival with the addition of HER2-targeted agents to chemotherapy, many patients do not benefit from these agents because of inherent resistance. In addition, many patients who achieve an initial response eventually acquire drug resistance. Currently, several mechanisms of resistance have been described, including mutations in other signaling pathways, expression of a truncated form of HER2, receptor crosstalk, and autophagy. There are several approaches under study to target these pathways of resistance, including blocking PI3 kinase and mammalian target of rapamycin signaling, blocking neoangiogenesis and the vascular endothelial growth factor axis, using monoclonal antibody targeting of the HER2 dimerization site, and using HER2 monoclonal antibody-drug conjugates. Here we will review the current scientific rationale for these agents and how combinations of these agents may yield additive or synergistic effects and lead to improved outcomes for patients with HER2-amplified breast cancer.
Insights
HER2-amplified breast cancer treatments face resistance. New strategies targeting resistance pathways, like PI3K/mTOR and VEGF, show promise for improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Human epidermal growth factor receptor 2 (HER2) amplification occurs in 20-30% of invasive breast cancers, correlating with metastasis and poorer survival.
- Approved HER2-targeted therapies (trastuzumab, lapatinib) improve survival but face inherent and acquired drug resistance.
- Mechanisms of resistance include signaling pathway mutations, truncated HER2 forms, receptor crosstalk, and autophagy.
Purpose of the Study:
- To review the scientific rationale for novel HER2-targeted agents.
- To explore combination strategies for overcoming resistance in HER2-amplified breast cancer.
- To identify potential improvements in patient outcomes through novel therapeutic approaches.
Main Methods:
- Review of current scientific literature on HER2-targeted therapies and resistance mechanisms.
- Analysis of emerging therapeutic strategies targeting resistance pathways.
- Evaluation of potential additive or synergistic effects of combination therapies.
Main Results:
- Multiple resistance mechanisms to current HER2-targeted therapies have been identified.
- Several novel therapeutic approaches are under investigation to overcome these resistance mechanisms.
- Combination therapies targeting resistance pathways (e.g., PI3K/mTOR, VEGF) show potential for enhanced efficacy.
Conclusions:
- Overcoming resistance is critical for improving outcomes in HER2-amplified breast cancer.
- Targeting specific resistance pathways and utilizing combination therapies represent promising strategies.
- Further research into these novel agents and combinations is warranted to improve patient survival and treatment efficacy.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...